Genes may predict toxicity to leukaemia therapy:
This article was originally published in Clinica
US researchers have identified genetic variations - polymorphisms - that could cause children with acute lymphoblastic leukaemia (ALL) to react badly to some chemotherapy drugs. The findings could help patients avoid harmful and potentially life-threatening side-effects of these drugs, and potentially allow doctors to individualise ALL chemotherapy according to each patient. "Such individualised therapy would eliminate the time-consuming trial-and-error approach to finding the right dose for a patient," said researcher Mary Relling, of St Jude's Children's Research Hospital in Memphis, Tennessee. The researchers identified 16 polymorphisms within genes that are known to affect the influence the pharmacodynamics of the drug in the body. The findings are published in the May 15 issue of Blood.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.